Current and former commissioners note their positive expectations for the coming year and discuss efforts to standardize drug review and globalize filing of generics, while Janet Woodcock strikes a more sober tone on the ‘limitations of what both government and medicine can do.’
US Food and Drug Administration Commissioner Robert Califf and three of his predecessors shared what they think will be positive developments in the new year, including continued health improvements from GLP-1 obesity treatments and a resurgence in drugs targeting mental health disorders.
Califf, former acting commissioner Janet Woodcock, and former commissioners Scott Gottlieb and Mark McClellan spoke on a panel at the...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
